The Biologic Association kicked off its very 1st Summit (Feb 5-7, 2020 in Carlsbad, CA) with what turned out to be a big crowd-pleaser. Initially set up as a “by invitation only” attendance, the Summit’s opening program, “Biologic Association Think Tank” raised such a high level of interest that everyone in attendance was ultimately let into the session.

The format for the Think Tank was quite similar to the hugely popular television show “Shark Tank.” Only in this session, the “school of fish” (contestants/presenters) included a lineup of industry and/or academic researchers in the field of Orthobiologics who gave presentations on their respective lead product candidates.

Robotics and other enabling technologies continued to drive implant sales for existing competitors in Q419, with several new product introductions and expanded applications expected in 2020 and beyond.

As Covid-19 tightens its grip on the global community, the impact on the world economy grows. SmartTRAK's analysts are constantly monitoring the effect COVID-19 is having on the Life Sciences industry, sifting through the noise to present the most relevant news to its subscribers. Our analysts continue to publish real-time updates throughout the day, detailing what you need to know about the impact the international healthcare crisis is having on the industry at large.

Following is a selection of the COVID-19 updates from the past week as compiled by the analysts at SmartTRAK:

COVID-19 Could Travel in Air Up to 13 Feet
New research published by the CDC showed COVID-19 was detected in air up to 4 m (~13 feet) from pts in a study that tested surface and air samples from a hospital w/ COVID-19 pts in Wuhan, China. The virus was detected on floors, computer mice, doorknobs, bed rails & trash cans.

A report by former FDA commissioner Scott Gottlieb, MD and colleagues at the American Enterprise Institute provides a roadmap for navigating through the COVID-19 pandemic in the US and outlines steps needed to start reopening America for businesses and families. AEI

DSM Launches Site to Support COVID-19 Efforts
With COVID-19 disrupting supply chains and causing shortages, DSM has launched a web page that brings together designs and resources for people looking to help alleviate the supply issues using 3D printing technology.

New research shows excellent results for anatomic TSA using a stemless humeral component with an inlay glenoid. Dr. Gregory Nicholson gives the breakdown on the research, indications, market acceptance and limitations. 

In the market for total shoulder arthroplasty (TSA), younger, active patients with degenerative conditions of the glenohumeral joint are a unique and more complicated population for surgeons to treat with TSA. Challenges in treating this cohort include higher functional demands that can lead to implant wear and failure. However, a recent study suggests a new implant design might be a good option these types of patients, potentially filling a treatment gap and expanding the market for TSA.

The US market for Hemostats and Sealants grew +5.8% YoY in Q419, comparable to its +6.2% growth in Q319, with continued strength in fibrin sealants and good growth in absorbable hemostats.

As reported in SmartTRAK Financial Dashboard, the US Hemostats and Sealants market maintained a solid growth rate of +5.8% in Q419 and grew +5.7% YoY. Leading the way in Q419 was Becton Dickinson (BD),  as its relaunch of Progel continued its resurgence. Baxter also posted strong gains.

Among the many topics covered in the comprehensive Q419/FY19 US Hemostats and Sealants Market Recap* are:

Tough comps and pricing pressure dampen growth during Q419

According to BioMedGPS’ SmartTRAK Financial Dashboard, the WW Trauma Market posted +2.8% growth, down from Q3, while the US achieved growth of +3.8%, also down from Q3. Trauma market leader DePuy Synthes (48.6% US Q4 share) reported while sales were down compared to Q319, gains were driven by overall market growth and strong adoption of their Femoral Neck System.

Tough comparisons, both YoY and sequentially, impacted the Q419 Trauma Market. The US pricing environment remains relatively steady as DePuy Synthes noted pricing pressure of -2.0%, in line with their Q2 and Q3 pricing (Q1 was -2.5%). Zimmer Biomet’s SET pricing improved in Q4 at -1.8% vs. Q3’s -2.0%. BioMedGPS believes 2019 pricing trended at -2.0 to -2.5%.

Among the many topics covered in the comprehensive Q419/FY19 Trauma Market Recap* are:

Covid-19 continues to spread across the globe, and, like the rest of the world, the MedtTech industry is strategizing the best ways to deal with the pandemic. SmartTRAK's analysts continue to monitor the effect COVID-19 is having on the Life Sciences industry, sifting through the noise to present the most relevant news to its subscribers and report on the impact the global healthcare crisis is having on the industry at large.

Following is a selection of the COVID-19 updates from the past week as compiled by the analysts at SmartTRAK:

OTA COVID-19 Webinar

• OTA Special Webinar COVID-19: Preparedness in Orthopaedic Trauma OTA Panel Discussion was held 4/2/10. Panel included 9 OTA Trauma surgeons. For a recording of the Webinar, go to: COVID-19: Preparedness in Orthopaedic Trauma OTA Panel Discussion.
• As a result of COVID-19 and stay at home orders, trauma surgeons are seeing a definite decrease in volumes, with polytrauma being almost negligible in certain cities. Geriatric fractures have decreased but to a lesser extent according to the OTA COVID-19 Webinar discussion.
• According to the OTA webinar panel discussions, trauma surgeons are taking resource allocation into consideration when assessing fracture care of the clavicle, humeral shaft or fibula and deciding whether to treat conservatively vs. operate in areas with COVID-19 surges.

COVID-19 Risks to Clinical Trials
The impact of COVID-19 has been immense. This article reviews eight significant risks COVID-19 poses to clinical trials and how to mitigate them.

COVID-19: Projections of Peak and Procedure Returns
The Institute for Health Metrics and Evaluation is now projecting lower overall hospital resource needs in the US and predicts the peak will be April 15. Based on this, WFS estimates elective procedures will be depressed through June.

Surprises lead to deceleration of overall Orthobio growth

For Q419, US Orthobio market growth (comprised of Bone, Cartilage, Soft Tissue and Meniscus Replacement implants) was flat at 0.3%. FY19 grew 4.2% over 2018. Both Q4 and FY19 did see shifts within the market. The double-digit growth of Cartilage and Wright’s AUGMENT was offset by lower than expected sales in Infuse, Cartiva SCI and soft tissue augmentation. For 2019, Medtronic remained the overall US market leader, followed by DePuy Synthes and Stryker.

Among the many topics covered in the comprehensive Q419/FY19 OrthoBio Market Recap* are:

As the COVID-19 pandemic progresses, the MedTech industry is continuing to see a multitude of changes and disruptions worldwide. SmartTRAK's analysts continue to monitor the effect COVID-19 is having on the Life Sciences industry, sifting through the noise to present the most relevant news to its subscribers and report on the impact the global healthcare crisis is having on the industry at large.

Following is a selection of the COVID-19 updates from the past week as compiled by SmartTRAK:

Surgeon Survey: COVID-19 Impact

• A survey of 50 orthopedic surgeons reported ~40% are still seeing both new and existing pts, while a third is only seeing pts for emergency or urgent issues. Telemedicine adoption has accelerated w/ 32% of survey takers noting some recent use. Canaccord Genuity Industry Report
• According to a 50-surgeon survey, postponements of orthopedic procedures have led to a sharp decline in pt volumes, w/ respondents indicating a 58% avg decline in March and an anticipated 77% avg decline in April. Canaccord Genuity Industry Report
• According to a 50-surgeon survey, 60% indicated that their organizations had already made formal decisions to defer or postpone orthopedic procedures, w/ ~33% indicating that over 90% of their entire practice was deferrable. Canaccord Genuity Industry Report
  
  

• SmartTRAK physician checks suggest elective procedure volumes for aneurysm cases will pick up in H219, assuming social isolation and other non- pharmaceutical interventions effectively reduce the spread of COVID-19 and healthcare demand.
• SmartTRAK is hearing from neurointerventionalists that COVID-19 is affecting elective procedure volumes for aneurysm cases, but those patients are being rescheduled—not canceled. Mechanical thrombectomy procedures have not been impacted to date.

The US Surgical Matrices Market showed robust growth in Q419, improving on Q319. Breast matrices rebounded from its Q319 malaise, while hernia matrices grew YoY.

• Q419 Breast Matrices market found its groove again, up YoY. For FY19 Breast Matrices grew well, despite several weak quarters.
• Q419 US Hernia Matrices market increased its growth, with the highest growth rate in biosynthetics and with both xenografts and allografts showing surprising strength. For the year, Hernia Matrices edged up.
• Allergan beat its supply constraints and maintained its leadership of the Breast Matrices market, as Alloderm returned to the market in force. For the full year, Allergan slid due to those Alloderm supply problems.
• BD maintained its No. 1 position in the Q419 Hernia Matrices market.

Among the many topics covered in the comprehensive Q419/FY19 US Surgical Matrices Market Recap* are: